{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:38:05Z","timestamp":1790534285440,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.radonc.2022.01.024","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:07:12Z","timestamp":1643407632000},"page":"130-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study"],"prefix":"10.1016","volume":"168","author":[{"given":"H. Jervoise N.","family":"Andreyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Gothard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lucy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Tovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvakumar","family":"Anbalagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Musallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yarnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahja Ahmed","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hauer-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.01.024_b0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/SPC.0b013e328343ad2f","article-title":"Manipulating the consequential effect: an alternative approach to reducing pelvic radiation disease other than dose reduction","volume":"5","author":"Wedlake","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.radonc.2022.01.024_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/SPC.0b013e32834e3bc1","article-title":"Biomarkers of normal tissue toxicity after pelvic radiotherapy","volume":"6","author":"Henson","year":"2012","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.radonc.2022.01.024_b0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2014.56.6539","article-title":"Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis","volume":"33","author":"Downing","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0020","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrgastro.2014.158","article-title":"Radiation enteropathy-pathogenesis, treatment and prevention","volume":"11","author":"Hauer-Jensen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2022.01.024_b0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1667\/RR14272.1","article-title":"GI consequences of cancer treatment: A clinical perspective","volume":"185","author":"Andreyev","year":"2016","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2022.01.024_b0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0360-3016(03)01445-7","article-title":"Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer","volume":"58","author":"O'Brien","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0040","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(13)61648-7","article-title":"Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial","volume":"382","author":"Andreyev","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.radonc.2022.01.024_b0045","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.radonc.2008.09.019","article-title":"Morbidity of prostate radiotherapy: Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial","volume":"90","author":"Capp","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0050","doi-asserted-by":"crossref","unstructured":"Lawrie TA, Green J, Beresford M, Wedlake L, Burden S, Davidson SE, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018 (1469-493X (Electronic)).","DOI":"10.1002\/14651858.CD012529.pub2"},{"key":"10.1016\/j.radonc.2022.01.024_b0055","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ijrobp.2004.12.087","article-title":"Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?","volume":"62","author":"Andreyev","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7861\/clinmedicine.16-3-240","article-title":"The holistic management of consequences of cancer treatment by a gastrointestinal and nutrition team: a financially viable approach to an enormous problem?","volume":"16","author":"Muls","year":"2016","journal-title":"Clin Med"},{"key":"10.1016\/j.radonc.2022.01.024_b0065","first-page":"2255","article-title":"Structured gastroenterological intervention and improved outcome for patients with chronic gastrointestinal symptoms following pelvic radiotherapy","volume":"21","author":"Henson","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.radonc.2022.01.024_b0070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clon.2006.12.007","article-title":"Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats","volume":"19","author":"Bese","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2022.01.024_b0075","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1200\/JCO.1999.17.10.3283","article-title":"Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol","volume":"17","author":"Delanian","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2008.04.042","article-title":"Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol","volume":"72","author":"Boerma","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0085","doi-asserted-by":"crossref","first-page":"e68762","DOI":"10.1371\/journal.pone.0068762","article-title":"Effects of late administration of pentoxifylline and tocotrienols in an image-guided rat model of localized heart irradiation","volume":"8","author":"Sridharan","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2022.01.024_b0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0360-3016(90)90549-Y","article-title":"Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis","volume":"19","author":"Dion","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0360-3016(93)90027-S","article-title":"Trental (pentoxifylline) relieves pain from postradiation fibrosis","volume":"25","author":"Werner-Wasik","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0100","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1200\/JCO.2004.09.101","article-title":"Pentoxifylline in the treatment of radiation-induced fibrosis","volume":"22","author":"Okunieff","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0105","unstructured":"Gottlober P, Krahn G, Korting HC, Stock W, Peter RU. [The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report]. Strahlenther Onkol. 1996;172:34-8."},{"key":"10.1016\/j.radonc.2022.01.024_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0167-8140(94)90444-8","article-title":"Successful treatment of radiation-induced fibrosis using liposomal Cu\/Zn superoxide dismutase: clinical trial","volume":"32","author":"Delanian","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.radonc.2005.09.014","article-title":"Pentoxifylline and vitamin E combination for superficial radiation-induced fibrosis: a phase II clinical trial","volume":"77","author":"Haddad","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hed.20121","article-title":"Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial","volume":"27","author":"Delanian","year":"2005","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2022.01.024_b0125","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2003.06.064","article-title":"Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis","volume":"21","author":"Delanian","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0130","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ijrobp.2005.05.063","article-title":"A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer","volume":"63","author":"Hille","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0135","unstructured":"Magnusson M, H\u00f6glund P, Johansson K, J\u00f6nsson C, Killander F, Malmstr\u00f6m P, et al. Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5). (1879-0852 (Electronic))."},{"key":"10.1016\/j.radonc.2022.01.024_b0140","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.radonc.2005.02.002","article-title":"Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy","volume":"75","author":"Gothard","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2004.09.013","article-title":"Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer","volume":"73","author":"Gothard","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2008.01.012","article-title":"Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial","volume":"20","author":"Venkitaraman","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2022.01.024_b0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2020.01.002","article-title":"Randomized, placebo-controlled clinical trial combining pentoxifylline-tocopherol and clodronate in the treatment of radiation-induced plexopathy","volume":"107","author":"Delanian","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12263-011-0228-8","article-title":"Mechanisms underlying the radioprotective properties of \u03b3-tocotrienol: comparative gene expression profiling in tocol-treated endothelial cells","volume":"7","author":"Berb\u00e9e","year":"2012","journal-title":"Genes Nutr"},{"key":"10.1016\/j.radonc.2022.01.024_b0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/09553000902985128","article-title":"Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector","volume":"85","author":"Ghosh","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2022.01.024_b0170","unstructured":"Berb\u00e9e M, Boerma M, Wang J, Kumar KS, Hauer-Jensen M. gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. (0033-7587 (Print))."},{"key":"10.1016\/j.radonc.2022.01.024_b0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1667\/RR2399.1","article-title":"Pentoxifylline enhances the radioprotective properties of \u03b3-tocotrienol: differential effects on the hematopoietic, gastrointestinal and vascular systems","volume":"175","author":"Berb\u00e9e","year":"2011","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2022.01.024_b0180","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3177\/jnsv.52.473","article-title":"Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E","volume":"52","author":"Rasool","year":"2006","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"10.1016\/j.radonc.2022.01.024_b0185","first-page":"1","article-title":"Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults: A randomized controlled study","volume":"8","author":"Chin","year":"2011","journal-title":"Nutr Metablism"},{"key":"10.1016\/j.radonc.2022.01.024_b0190","doi-asserted-by":"crossref","unstructured":"Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, et al. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012:513-9.","DOI":"10.3945\/jn.111.151902"},{"key":"10.1016\/j.radonc.2022.01.024_b0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/flgastro-2014-100468","article-title":"The practical management of the gastrointestinal symptoms of pelvic radiation disease","volume":"6","author":"Andreyev","year":"2015","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.radonc.2022.01.024_b0200","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ijrobp.2005.10.007","article-title":"A modified Inflammatory Bowel Disease Questionnaire and the Vaizey Incontinence Questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading","volume":"64","author":"Khalid","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.024_b0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12032-019-1334-5","article-title":"Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study","volume":"37","author":"Sayed","year":"2019","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2022.01.024_b0210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00066-005-1390-y","article-title":"Effect of pentoxifylline and tocopherol on radiation proctitis\/enteritis","volume":"181","author":"Hille","year":"2005","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2022.01.024_b0215","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/carcin\/bgr261","article-title":"Tocotrienol as a potential anticancer agent","volume":"33","author":"Ling","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.radonc.2022.01.024_b0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1211\/0022357011775208","article-title":"Pharmokinetics and bioavailability of alpha, gamma and delta tocotrienols under different food status","volume":"53","author":"Yap","year":"2001","journal-title":"JPP"},{"key":"10.1016\/j.radonc.2022.01.024_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-7075-11-5","article-title":"Bioavailability of tocotrienols: evidence in human studies","volume":"11","author":"Fu","year":"2014","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.radonc.2022.01.024_b0230","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1200\/JCO.2005.02.4729","article-title":"Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis","volume":"23","author":"Delanian","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:20:42Z","timestamp":1759123242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":46,"alternative-id":["S0167814022000299"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.01.024","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomised single centre double-blind placebo controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}